StablevaX™ is a disruptive platform technology that aims to produce fridge-free vaccines to eliminate the need for the global cold chain, reduce vaccine wastage and save lives through better immunisation
Telegraph explores British Research into Monkeypox and Stablepharma's fridge-free vaccine technologiesStablepharma & World Leader in Sterile Manufacturing Announce Partnership to Manufacture the first Fridge-Free Td Vaccine
A child dying every 20 seconds is an unacceptable statistic. Stablepharma is The Fridge-Free Vaccine Company, committed to launching the world’s first fridge-free vaccines, eliminating the need for the cold chain and enabling stockpiling anywhere in the world.
Our novel patented StablevaX™ technology is designed to dramatically enhance the performance of existing and new vaccines, thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration.
Stablepharma’s fridge-free vaccines can help expand access to patients and increase the success of immunisation programmes.
Latest Press Coverage on StablevaX™
Stablepharma Technology
StablevaX™ is a patented product that aims for enhanced thermostability, following WHO protocols
Zero Refrigeration
StablevaX™ technology aims to eliminate the need for refrigeration
Thermostable Vaccines
StablevaX™ technology is designed with the aim of administering to patients without any change to current practice
Our white paper
StablevaX™ - a complementary technology for COVID-19 vaccines
In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never been starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.
